Q3 FY26 results: Revenue and profit decline; director re-appointment
LXCHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts more than Nifty Microcap 250 and 1.8 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Q3 FY26 standalone revenue Rs 707 cr, down 8% YoY. 9M revenue Rs 2,085 cr, down 7%. Standalone 9M PAT Rs 57 cr vs Rs 90 cr (down 37%). Consolidated 9M PAT Rs 58 cr vs Rs 92 cr. Key tailwinds: Rs 407 cr electricity liability reversal and Rs 234 cr GST incentive recognition. Comparatives restated for subsidiary YFCPL merger. Board approved re-appointment of Independent Director Dr. Rajiv Banavali.
Revenue and profit declines are concerning, but one-off items (electricity reversal, GST incentive) boosted earnings. Watch underlying operating performance.